It simultaneously blocks CTLA-4 with CD80/85 and PD-L1 with programmed cell death-1 (PD-1) to inhibit immunosuppressive effects, which restores T-cell effector immune response to tumor and deletes Treg cells (suppress tumor immunity) in tumor microenvironment. Here, CD80 is linked to neoplasm.